SORRENTO THERAPEUTICS INC (SRNE) Stock Overview
USA - NASDAQ:SRNE - US83587F2020 - Common Stock
SRNE Key Statistics, Chart & Performance
The current stock price of SRNE is 0.3073 USD. In the past month the price decreased by -69.57%. In the past year, price decreased by -88.14%.
SRNE Latest News, Press Relases and Analysis
SRNE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.5 | 402.21B | ||
| AMGN | AMGEN INC | 13.27 | 155.80B | ||
| GILD | GILEAD SCIENCES INC | 15.53 | 149.13B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.88 | 108.06B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.79 | 61.86B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 63.09B | ||
| ARGX | ARGENX SE - ADR | 90.23 | 51.16B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.07 | 34.51B | ||
| INSM | INSMED INC | N/A | 34.49B | ||
| NTRA | NATERA INC | N/A | 26.38B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.38B | ||
| BIIB | BIOGEN INC | 9.36 | 21.98B |
Related stock screener links
About SRNE
Company Profile
Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. The company is headquartered in San Diego, California and currently employs 799 full-time employees. The company went IPO on 2007-01-19. The Company’s segments include Sorrento Therapeutics and Scilex. Sorrento Therapeutics segment is organized around Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate cancer therapeutics. The Scilex segment is largely organized around its non-opioid pain management operations. The Company’s immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), clinical- stage immuno-cellular therapies (CAR-T, DAR-T), antibody-drug conjugates (ADCs) and clinical-stage oncolytic virus (Seprehvir). The firm is also developing potential antiviral therapies and vaccines against coronaviruses, including Abivertinib, COVI-AMG, COVISHIELD, COVI-MSC and COVIDROPS, and diagnostic test solutions, including COVITRACK and COVISTIX.
Company Info
SORRENTO THERAPEUTICS INC
4955 Directors Place
San Diego CALIFORNIA 92121 US
CEO: Henry Ji
Employees: 799
Phone: 18582034100.0
SORRENTO THERAPEUTICS INC / SRNE FAQ
What does SORRENTO THERAPEUTICS INC do?
Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. The company is headquartered in San Diego, California and currently employs 799 full-time employees. The company went IPO on 2007-01-19. The Company’s segments include Sorrento Therapeutics and Scilex. Sorrento Therapeutics segment is organized around Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate cancer therapeutics. The Scilex segment is largely organized around its non-opioid pain management operations. The Company’s immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), clinical- stage immuno-cellular therapies (CAR-T, DAR-T), antibody-drug conjugates (ADCs) and clinical-stage oncolytic virus (Seprehvir). The firm is also developing potential antiviral therapies and vaccines against coronaviruses, including Abivertinib, COVI-AMG, COVISHIELD, COVI-MSC and COVIDROPS, and diagnostic test solutions, including COVITRACK and COVISTIX.
What is the current price of SRNE stock?
The current stock price of SRNE is 0.3073 USD. The price decreased by -20.26% in the last trading session.
Does SRNE stock pay dividends?
SRNE does not pay a dividend.
What is the ChartMill rating of SORRENTO THERAPEUTICS INC stock?
SRNE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists SRNE stock?
SRNE stock is listed on the Nasdaq exchange.
Can you provide the sector and industry classification for SORRENTO THERAPEUTICS INC?
SORRENTO THERAPEUTICS INC (SRNE) operates in the Health Care sector and the Biotechnology industry.
What is the Price/Earnings (PE) ratio of SORRENTO THERAPEUTICS INC (SRNE)?
SORRENTO THERAPEUTICS INC (SRNE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.43).
SRNE Technical Analysis
SRNE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SRNE. SRNE may be in some trouble as it scores bad on both profitability and health.
SRNE Financial Highlights
Over the last trailing twelve months SRNE reported a non-GAAP Earnings per Share(EPS) of -1.43. The EPS decreased by -20.17% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0.14 |
SRNE Forecast & Estimates
9 analysts have analysed SRNE and the average price target is 7.82 USD. This implies a price increase of 2444.75% is expected in the next year compared to the current price of 0.3073.
For the next year, analysts expect an EPS growth of 15.83% and a revenue growth 3.85% for SRNE